S&P 500
$5,842.01
-0.0%
-$2.60
DJI
41,859.09
-0.0%
-1.35
NASDAQ
$18,925.73
+0.3%
+$53.09
Bitcoin
110,784.00
-0.6%
-646.55
AAPL
$201.16
-0.5%
-$0.93
AMZN
$202.96
+0.9%
+$1.84
GOOG
$171.96
+1.1%
+$1.90
META
$636.81
+0.2%
+$1.31
MSFT
$454.60
+0.4%
+$2.03
NVDA
$132.90
+0.8%
+$1.10
TSLA
$341.59
+2.1%
+$6.97
Nuvectis Pharma (NASDAQ: NVCT)
$9.96
(-0.9%)
-$0.09
Price as of May 22, 2025, 3:58 p.m. ET
Nuvectis Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Nuvectis Pharma Company Info
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.